Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright

Intellia Therapeutics (NASDAQ:NTLA) had its price target dropped by equities research analysts at HC Wainwright from $30.00 to $25.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 78.70% from the company’s previous close.

A number of other research analysts have also recently issued reports on the stock. Bank of America restated a “neutral” rating on shares of Intellia Therapeutics in a report on Monday, March 2nd. Leerink Partners set a $35.00 price target on shares of Intellia Therapeutics in a research note on Monday, April 27th. KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, January 28th. Citigroup reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 28th. Finally, William Blair raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.14.

Intellia Therapeutics Trading Down 3.0%

NTLA opened at $13.99 on Wednesday. The stock has a market capitalization of $1.69 billion, a PE ratio of -3.95 and a beta of 1.93. Intellia Therapeutics has a 1-year low of $6.83 and a 1-year high of $28.25. The firm has a 50-day moving average price of $13.67 and a two-hundred day moving average price of $12.15.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 55.63%. The company had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. On average, research analysts predict that Intellia Therapeutics will post -3.5 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC acquired a new position in shares of Intellia Therapeutics in the third quarter valued at $10,486,000. SG Americas Securities LLC grew its stake in shares of Intellia Therapeutics by 239.7% in the third quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock valued at $2,264,000 after acquiring an additional 92,485 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Intellia Therapeutics by 1.8% in the third quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock valued at $190,744,000 after acquiring an additional 192,651 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new position in shares of Intellia Therapeutics in the third quarter valued at about $23,519,000. Finally, Contrarius Group Holdings Ltd grew its stake in shares of Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after acquiring an additional 4,337,428 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.